The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Open accessAbstract
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis. METHODS: We randomly assigned 1326 patients in an approximate 1:1:1 ratio to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for the first 48 weeks, then in two short courses starting at week 48 and week 52 (for a total of 8 to 20 days per year). The primary end point was the rate of relapse at 96 weeks. RESULTS: Among patients who received cladribine tablets (either 3.5 mg or 5.25 mg per kilogram), there was a significantly lower annualized rate of relapse than in the placebo group (0.14 and 0.15, respectively, vs. 0.33; P<0.001 for both comparisons), a higher relapse-free rate (79.7% and 78.9%, respectively, vs. 60.9%; P<0.001 for both comparisons), a lower risk of 3-month sustained progression of disability (hazard ratio for the 3.5-mg group, 0.67; 95% confidence interval [CI], 0.48 to 0.93; P=0.02; and hazard ratio for the 5.25-mg group, 0.69; 95% CI, 0.49 to 0.96; P=0.03), and significant reductions in the brain lesion count on magnetic resonance imaging (MRI) (P<0.001 for all comparisons). Adverse events that were more frequent in the cladribine groups included lymphocytopenia (21.6% in the 3.5-mg group and 31.5% in the 5.25-mg group, vs. 1.8%) and herpes zoster (8 patients and 12 patients, respectively, vs. no patients). CONCLUSIONS: Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. (ClinicalTrials.gov number, NCT00213135.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Cladribine (2-chlorodeoxyadenosine)
Beutler, E. (1992) · The Lancet · doi:10.1016/0140-6736(92)92826-2 · Cited by 348
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
Rice, G. P. A., Filippi, M., Comi, G., & for the Cladribine Clinical Study Group and for the Cladribine MRI Study Group* (2000) · Neurology · doi:10.1212/wnl.54.5.1145 · Cited by 325
Self-citationThe contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
Fazekas, F., Barkhof, F., Filippi, M., Grossman, R. I., Li, D. K. B., McDonald, W. I., McFarland, H. F., Paty, D. W., Simon, J. H., Wolinsky, J. S., et al. (1999) · Neurology · doi:10.1212/wnl.53.3.448 · Cited by 287
B cells and multiple sclerosis
Franciotta, D., Salvetti, M., Lolli, F., Serafini, B., & Aloisi, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70192-3 · Cited by 287
Cladribine in treatment of chronic progressive multiple sclerosis
SIPE, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91046-4 · Cited by 283
The treatment of chronic progressive multiple sclerosis with cladribine.
Beutler, E., Sipe, J. C., Romine, J. S., Koziol, J. A., McMillan, R., & Zyroff, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1716 · Cited by 208
The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis
Chitnis, T. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)79003-7 · Cited by 173
Romine, J. S., Sipe, J. C., Koziol, J. A., Zyroff, J., & Beutler, E. (1999) · Proceedings of the Association of American Physicians · doi:10.1046/j.1525-1381.1999.09115.x · Cited by 142
Cited by
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Self-citationMultiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Self-citationHow do immune cells overcome the blood-brain barrier in multiple sclerosis?
Larochelle, C., Alvarez, J. I., & Prat, A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.066 · Cited by 405
“sult in a decreased number of new gadolinium-enhancing lesions [3–6], supporting the concept that the overall state of peripheral immune cell activation leads to BBB dysfunction.”
BackgroundMultiple Sclerosis: Pathogenesis and Treatment
Loma, I., & Heyman, R. (2011) · Current Neuropharmacology · doi:10.2174/157015911796557911 · Cited by 350
Treatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Giovannoni, G., Soelberg Sorensen, P., Cook, S., Rammohan, K., Rieckmann, P., Comi, G., Dangond, F., Adeniji, A. K., & Vermersch, P. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517727603 · Cited by 338
Self-citationThe Immune Response in Multiple Sclerosis
Rodríguez Murúa, S., Farez, M. F., & Quintana, F. J. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052920-040318 · Cited by 335
Sormani, M. P., Arnold, D. L., & De Stefano, N. (2014) · Annals of Neurology · doi:10.1002/ana.24018 · Cited by 297
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 289
Self-citationB cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
Giovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., & Greenberg, S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70023-0 · Cited by 252
Self-citationLeist, T. P., Comi, G., Cree, B. A. C., Coyle, P. K., Freedman, M. S., Hartung, H.-P., Vermersch, P., Casset-Semanaz, F., & Scaramozza, M. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70005-5 · Cited by 252
Self-citationAging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?
Mayne, K., White, J. A., McMurran, C. E., Rivera, F. J., & de la Fuente, A. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572090 · Cited by 167
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Al-Izki, S., Pryce, G., O'Neill, J. K., Butter, C., Giovannoni, G., Amor, S., & Baker, D. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2011.09.001 · Cited by 73
Self-citationDiagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
Geladaris, A., Torke, S., & Weber, M. S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00951-z · Cited by 45
“Considering the fact that cladribine is only given a few treatment days per year and the estimated terminal half-life of cladribine is only 1 day [8, 9] it remains unclear if the drug causes long-lasting changes in the absence of ongoing direct drug-related effects.”
BackgroundBrieva, L., Calles, C., Landete, L., & Oreja-Guevara, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543649 · Cited by 16
Insights and challenges on animal models for progressive multiple sclerosis
Nalepa, I. F., Haahr, N. O., Bekiaris, V., Jakobsen, M. R., Asuni, A. A., & Benmamar-Badel, A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03805-3 · Cited by 1
Schiavetti, I., Signori, A., Albanese, A., Frau, J., Cocco, E., Lorefice, L., di Lemme, S., Fantozzi, R., Centonze, D., Landi, D., et al. (2026) · European Journal of Neurology · doi:10.1111/ene.70763
Metadata
- Authors
- Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Chang, P., Hamlett, A., Musch, B., & Greenberg, S. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-02-04
- Volume
- 362
- Issue
- 5
- Pages
- 416-426
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139204856
- Cited by
- 1,023
- References
- 12
- FWCI
- 49.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.